Reuters logo
BRIEF-Pharming and Salix say FDA extended PDUFA date for angioedema drug Ruconest
February 24, 2014 / 6:10 AM / 4 years ago

BRIEF-Pharming and Salix say FDA extended PDUFA date for angioedema drug Ruconest

AMSTERDAM, Feb 24 (Reuters) - Pharming Group NV : * FDA extends prescription drug user fee act date for co’s biologics license

application for drug Ruconest * FDA extends date to July 16, 2014 * Cos U.S. marketing approval of Ruconest that treats acute angioedema attacks in patients with hereditary angioedema

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below